Bullish
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression
GH Research PLC announced new clinical data for its inhaled mebufotenin candidate, GH001, in mood disorders. The company highlighted the publication o...